Volume 51, Issue 1, Pages (January 2007)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Volume 60, Issue 4, Pages (October 2011)
Volume 52, Issue 1, Pages (July 2007)
The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis  Maria I. Carlo, Darren R.
Volume 55, Issue 2, Pages (February 2009)
Renal Cell Carcinoma: Prognostic Factors and Patient Selection
Volume 67, Issue 5, Pages (May 2015)
Volume 71, Issue 2, Pages (February 2017)
Volume 69, Issue 1, Pages (January 2016)
Volume 69, Issue 1, Pages 4-6 (January 2016)
Histologic Grading of Noninvasive Papillary Urothelial Neoplasms
Let the Games Begin (with EAU Approval)
Volume 68, Issue 1, Pages (July 2015)
Prostate Cancer Epidemic in Sight?
Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer  Olav Erich Yri, Trine Bjoro, Sophie D.
Volume 60, Issue 4, Pages (October 2011)
Volume 66, Issue 2, Pages (August 2014)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey  John B. McKinlay, Carol L. Link  European.
Volume 51, Issue 1, Pages (January 2007)
Volume 54, Issue 4, Pages (October 2008)
Volume 52, Issue 5, Pages (November 2007)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Volume 55, Issue 2, Pages (February 2009)
Volume 52, Issue 1, Pages (July 2007)
Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 68, Issue 1, Pages (July 2015)
Volume 63, Issue 5, Pages (May 2013)
International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia  Brett Delahunt, John R. Srigley, Lars Egevad,
Prostate Cancer Epidemic in Sight?
James N. Armitage, Stuart O. Irving, Neil A. Burgess  European Urology 
The PSA Era is not Over for Prostate Cancer
Volume 50, Issue 3, Pages (September 2006)
Volume 61, Issue 6, Pages (June 2012)
Volume 74, Issue 3, Pages (September 2018)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 51, Issue 5, Pages (May 2007)
Volume 49, Issue 5, Pages (May 2006)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 62, Issue 2, Pages (August 2012)
Volume 59, Issue 1, Pages (January 2011)
European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update
Volume 61, Issue 5, Pages (May 2012)
The Economic Costs of Overactive Bladder in Germany
Volume 46, Issue 6, Pages (December 2004)
Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl  European Urology 
Volume 50, Issue 5, Pages (November 2006)
Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma  Sergio Bracarda, Alain Ravaud, Marino.
Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma  Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,
Testicular Cancer Variations in Time and Space in Europe
Volume 152, Issue 1, (January 2013)
Sergio Bracarda  European Urology Supplements 
European Urology is “Your” Journal
Epidemiology of Renal Cell Carcinoma
Volume 51, Issue 6, Pages (June 2007)
Economic Burden of Bladder Cancer Across the European Union
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Annika Berntsen, Poul F. Geertsen, Inge Marie Svane  European Urology 
Bertrand Tombal, Richard Berges
Joaquim Bellmunt  European Urology Supplements 
Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita  Kidney International 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Jan Roigas  European Urology Supplements 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Volume 148, Issue 1, (January 2012)
Presentation transcript:

Volume 51, Issue 1, Pages 168-174 (January 2007) Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Endostatin in Renal Cell Carcinoma Patients Compared to a Control Group  Luigi Schips, Orietta Dalpiaz, Katja Lipsky, Cord Langner, Peter Rehak, Peter Puerstner, Karl Pummer, Richard Zigeuner  European Urology  Volume 51, Issue 1, Pages 168-174 (January 2007) DOI: 10.1016/j.eururo.2006.06.026 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Levels of VEGF in the different histologic subtypes. European Urology 2007 51, 168-174DOI: (10.1016/j.eururo.2006.06.026) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 Levels of endostatin in the different histologic subtypes. European Urology 2007 51, 168-174DOI: (10.1016/j.eururo.2006.06.026) Copyright © 2006 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.